New drug before surgery shows promise for hard-to-treat colon cancer
NCT ID NCT06686576
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called QL1706 given before surgery for people with a specific type of colon cancer (MSI-H/dMMR) that has not spread far. About 363 participants will receive either QL1706 or standard care. The goal is to see if QL1706 can eliminate more tumor tissue before surgery and improve long-term outcomes. Participants must have good organ function and no prior cancer treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Cancer Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Can artificial intelligence think like a cancer tumor board?
- A new clue in the fight against colorectal cancer recurrence?
- Can radiation plus immunotherapy make colon tumors disappear before surgery?
- Can a chemo boost outsmart lingering colon cancer cells?
- Does practice make perfect? a study probes how a Surgeon's learning curve impacts cancer surgery success